NRx Pharmaceuticals filed a petition with the FDA requesting the removal of the drug BZT.
1 report, 1 independent
Updated Aug 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
NRx Pharmaceuticals filed a petition with the FDA requesting the removal of the drug BZT.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- The FDA completed the first-cycle review of an Abbreviated New Drug Application (ANDA) involving NRx Pharmaceuticals and Teva.Sub-event
NRx Pharmaceuticals petitioned the FDA to remove BZT from its portfolio.1 source
Keep exploring
The entities involved
Related events
- NRx Pharmaceuticals is seeking regulatory approval from the FDA for its drug candidates, NRX-100 and NRX-101.
- BMD is listed on Nasdaq and received positive feedback from the FDA regarding its Phase 3 drug protocol.
- Argenx SE announced it is listed on Nasdaq and is seeking FDA priority review and approval.
Coverage
Newest first; wire copies grouped- NewMediaWireNRx Pharmaceuticals (NASDAQ: NRXP) Petitions FDA to Ban Benzethonium Chloride From Ketamine Products LOS ANGELES, CA - August 13, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-